Sanctuary Advisors’s Inhibikase Therapeutics IKT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-12,539
Closed -$25.7K 2576
2025
Q4
$25.7K Buy
+12,539
New +$20K ﹤0.01% 2398

Other funds holding IKT

Sanctuary Advisors's IKT Position: Q1 2026 in Review

Sanctuary Advisors sold out of Inhibikase Therapeutics (IKT) in Q1 2026, closing a stake of 12,539 shares — an estimated $25.7K sold.

Sanctuary Advisors first reported a position in IKT in Q4 2025 and held it in 1 quarter. The position peaked at $25.7K in Q4 2025. 104 funds tracked by Wall St. Rank hold IKT as of Q1 2026.

  • Sanctuary Advisors reported no remaining Inhibikase Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Sanctuary Advisors sold 12,539 Inhibikase Therapeutics shares in Q1 2026, an estimated $25.7K.
  • Sanctuary Advisors first reported a position in Inhibikase Therapeutics in Q4 2025 and held it in 1 quarter.
  • Sanctuary Advisors's Inhibikase Therapeutics position peaked at $25.7K in Q4 2025.
  • 104 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q1 2026.

Based on Sanctuary Advisors's 13F filing for Q1 2026, filed 5 May 2026.